<DOC>
	<DOCNO>NCT00743860</DOCNO>
	<brief_summary>This study design assess pharmacokinetics darapladib metabolite follow single 28 day repeat dose darapladib .</brief_summary>
	<brief_title>A Healthy Volunteer Pharmacokinetic Study Single Repeat Doses SB-480848</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Darapladib</mesh_term>
	<criteria>Healthy determine responsible physician , base medical evaluation include medical history , physical examination , laboratory test ECG . Male female 18 65 year age inclusive , time signing informed consent . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea Childbearing potential agrees use one contraception method per protocol appropriate period time prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception followup visit . Body weight &gt; 50 kg BMI within range 19 30 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . QTcB QTcF &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block . A positive prestudy drug/alcohol screen . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen A positive test HIV antibody . History regular alcohol consumption within 6 month study define average weekly intake &gt; 14 drink male &gt; 7 drink female . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication Consumption grapefruit grapefruit juice within 7 day prior first dose study medication . History drug abuse . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . History anaphylaxis , anaphylactoid ( resemble anaphylaxis ) reaction severe allergic response . History cholecystectomy biliary tract disease , history liver disease elevate liver function test know unknown etiology . History sensitivity heparin heparininduced thrombocytopenia ( heparin use flush cannula ) . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Use oral , injected implant hormonal method contraception female subject . Pregnant female determine positive serum hCG test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>darapladib</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>metabolite</keyword>
	<keyword>SB-480848</keyword>
</DOC>